Introduction
Polymorphonuclear and mononuclear phagocytes function in host defense against infections and recognize, ingest and destroy foreign materials and organisms. Pluripotent hematopoietic stem cells (HSC) give rise to a lin
þ FcgR lo common myeloid progenitor (CMP), which in turn gives rise to a lin
þ FcgR hi granulocyte-monocyte progenitor (GMP; Akashi et al., 2000; Traver et al., 2001) . The GMP population includes granulocyte-, monocyte-and predominantly granulocyte/monocyte-colony forming units (CFU-G, CFU-M and CFU-GM). CFU-G and CFU-M likely arise from CFU-GM, though direct development of CFU-M or CFU-G from CMP or HSC under some circumstances remains a formal possibility. GMPs also arise from a lin
þ lymphoid-myeloid progenitor (LMP; Adolfsson et al., 2005) . Fetal liver and adult marrow also harbor cells with combined B-lineage and monocyte/macrophage potential (Lacaud et al., 1998; Montecino-Rodriguez et al., 2001; Traver et al., 2001) . Monocytes not only develop into macrophages, but in addition give rise to osteoclasts and myeloid dendritic cells (Roodman, 1996; Manz et al., 2001 ).
An earlier review provided an overview of the transcriptional regulation of immature and mature granulocyte and monocyte lineage-specific genes (Friedman, 2002) . From that survey, it was apparent that CCAAT/enhancer-binding proteins (C/EBPs) and PU.1 regulate the large majority of myeloid genes and that AP-1 proteins activate at least a subset of monocytic genes. Although Runx1 and c-Myb regulate several genes in immature myeloid cells, they likely play a greater role in HSC biology. The current review will focus on progress over the last 5 years on regulation of myeloid lineage development by C/EBPa and PU.1 and by transcription factors and cytokine signals that interact directly or indirectly with these factors or further downstream in granulocyte or monocyte lineage development.
CCAAT/enhancer-binding protein a, b and e
The C/EBPs homo-and heterodimerize via their C-terminal leucine zipper (LZ) domains and bind DNA as obligate dimers via the adjacent basic regions (BR) . The co-crystal structure of the C/EBPa BR-LZ (bZIP) domain with its cognate binding site confirms that the bZIP domain is a continuous a-helix with residues 286-300 entering the major groove to make direct contact with the base pairs and the phosphate backbone (Miller et al., 2003) . The consensus binding site is 5 0 -T(T/G)NNGNAA(T/G)-3 0 . C/EBPa, C/EBPb and C/EBPd have N-terminal trans-activation domains, and translation initiation from internal methionines produces truncated, dominant-inhibitory polypeptides that retain the bZIP domain, but have an altered spectrum of preferred DNA-binding sites (Friedman et al., 1989; Friedman and McKnight, 1990; Descombes and Schibler, 1991; Lin et al., 1993; Calkhoven et al., 2000; Cleaves et al., 2004) . The Notch-induced protein Trib2 binds the 42 kDa but not the 30 kDa isoform of C/EBPa to induce its proteasome-mediated degradation (Keeshan et al., 2006) . Phosphorylation of C/EBPa serine 21 by extracellular signal-regulated kinase suppresses its activity (Ross et al., 2004) . C/EBPe has both trans-activation and trans-repression domains and is expressed as several alternatively spliced isoforms (Williamson et al., 1998; Lekstrom-Himes, 2001 ).
Within hematopoiesis, C/EBPa, C/EBPb and C/EBPd are predominantly expressed in the granulocyte, monocyte and eosinophil lineages (Scott et al., 1992; Muller et al., 1995; Radomska et al., 1998) . C/EBPa expression predominates in immature cells and is detected in the HSC, CMP and GMP, but not the common lymphoid (CLP) or megakeryocyte-erythroid progenitor (MEP) populations . C/EBPe is found in later-stage granulocytes (Antonson et al., 1996) . CHOP, a dominant-inhibitory C/EBP isoform is not expressed during normal granulopoiesis, but is induced by DNA damage or ER-stress and participates in the inflammatory response (Friedman, 1996; Endo et al., 2006) . C/EBPa(À/À) neonatal mice lack neutrophils and eosinophils; although they retain monocytes in their peripheral blood, Mac-1 þ /Gr-1 À monocytes are reduced in their fetal and newborn livers, and marrow CFU-M numbers are reduced twofold despite expression of the macrophage colony stimulating factor receptor (MCSFR; Zhang et al., 1997) . Consistent with these observations, Mx1-CRE-mediated deletion of C/EBPa in adult mice results in a block of the CMP to GMP transition . A separate study investigated myelopoiesis in independently generated C/EBPa(À/À) mice similarly concludes that lack of C/EBPa leads to a block between the CMP and GMP stage, based on increased CFU-S but reduced CFU-GM, neutrophils and monocyte/macrophages (Heath et al., 2004) . Lack of myelopoiesis in vivo from C/EBPa(À/À) progenitors may in part reflect reduced expression of the M-CSF and G-CSF Receptors, as each of their promoters depends upon C/EBPa for expression (Zhang et al., 1994; Smith et al., 1996) . A global inhibitor of C/EBP-induced trans-activation, KRAB-C/EBPa-ER, inhibits murine CFU-G, CFU-M and CFU-GM formation in interleukin (IL)-3 or GM-CSF and prevents 32Dcl3 granulocytic differentiation even in the presence of exogenous G-CSF receptor, indicating that C/EBP family members are required subsequent to induction of cytokine receptors for myelopoiesis (Wang and Friedman, 2002) . Expression of a dominant inhibitor of C/EBP DNA-binding in human progenitors similarly prevented the formation of G-CSF-, M-CSF-or GM-CSF-induced myeloid CFUs .
Beyond regulation lineage-specific genes, such as myeloperoxidase and neutrophil elastase (Nuchprayoon et al., 1994; Ford et al., 1996; Oelgeschla¨ger et al., 1996) , PU.1 and C/EBPe are two regulatory transcription factors whose mRNAs are rapidly induced by the C/EBPa-ER fusion protein even in cycloheximide, suggesting direct gene activation (Wang et al., 1999) . Indeed, C/EBPa binds and activates the PU.1 promoter and distal enhancer, and the role of this activation in myelopoiesis will be discussed further below Yeamans et al., 2007) . C/EBPe(À/À) mice develop all of the hematopoietic lineages, but have a defect in terminal neutrophil maturation resembling human cases of secondary granule deficiency (SGD; Yamanaka et al., 1997; Chumakov et al., 1997) , and human cases of SGD harboring C/EBPe point mutations have been described (Lekstrom-Himes et al., 1999; Gombart et al., 2001) . Defects in macrophage function are also present in C/EBPe(À/À) mice (Gombart et al., 2005) . C/EBPa binds the promoter of micro-RNA 223, which in turn suppresses translation of nuclear factor I-A to favor granulocytic maturation (Fazi et al., 2005) . C/EBPa also binds and activates its own promoter, perhaps reflecting a feedforward mechanism to fix commitment decisions (Christy et al., 1991) . As a further means of stabilizing commitment decisions, cross-inhibition of C/EBPa and Pax5 expression may stabilize transition of LMP to either the CLP or GMP stages, although the extent of such competition and the mechanisms involved require further investigation (Heavey et al., 2003; Xie and Graf, 2004; Hsu et al., 2006; Anderson et al., 2007) . Pax5 also represses the MCSFR promoter through direct interaction (Tagoh et al., 2006) .
Under some circumstances, C/EBPb can compensate for loss of C/EBPa during myelopoiesis. Expression of C/EBPb from the C/EBPa locus leads to normal hematopoiesis (Jones et al., 2002) . C/EBPa(À/À) fetal liver cells exposed in vivo to GM-CSF and IL-3 generate neutrophils, whereas knockdown of C/EBPb in these cells reduces their ability to do so (Hirai et al., 2006) . C/EBPb(À/À) marrow cells generate 25-50% reduced numbers of myeloid colonies compared with C/EBPb( þ /À) cells in various cytokine conditions, and the colonies formed are smaller, potentially reflecting an ability of C/EBPb to stimulate the proliferation of myeloid cells, as has been seen with other cell types (Hirai et al., 2006; Sebastian and Johnson, 2006) . Induction of C/EBPb in vitro may account for the ability of C/EBPa(À/À) cells cultured in IL-3 or GM-CSF, or transduced with the G-CSF receptor and cultured in G-CSF, to generate neutrophils .
In contrast to C/EBPb, C/EBPa potently inhibits G1 to S cell cycle progression in a variety of lineages, including myeloid cells (Umek et al., 1991; Wang et al., 1999) . C/EBPa inhibits cell proliferation via several mechanisms that may vary between cell lineages, including direct binding of E2F1 or cyclin-dependent kinase (cdk)2/cdk4 and induction of p21 (Johnson, 2005) . Interaction of E2F1 with the outer surface of the C/EBPa BR enables growth inhibition in myeloid cells and is required for their terminal differentiation (Porse et al., 2001 (Porse et al., , 2005 Wang et al., 2003) . Repression of the c-Myc gene by C/EBPa requires tethering of C/EBPa to the c-Myc promoter via DNA-bound E2F1 (Johansen et al., 2001) . The N terminus of C/EBPa is required for its E2F1-dependent cell cycle inhibition, potentially via interaction with a co-repressor, although further elucidation of the mechanism underlying this phenomenon is required (Porse et al., 2001) . C/EBPa gene knockout studies indicate a block in the CMP to GMP transition, but do not address the subsequent role of C/EBPa in monocyte versus granulocyte lineage commitment. The ability of exogenous C/EBPa and other C/EBPs to direct granulopoiesis from several myeloid cell lines led to early models depicting a more prominent role for C/EBPa during granulopoiesis than monopoiesis (Radomska et al., 1998; Wang et al., 1999; Wang and Friedman, 2002) . However, transduction of C/EBPa-ER into marrow mononuclear cells followed by lineage-depletion and then culture with or without estradiol leads to the finding that C/EBPa favors formation of monocytes over granulocytes in liquid culture and of CFU-M over CFU-G in methylcellulose culture, in IL3/IL-6/SCF or GM-CSF . Use of a regulated C/EBPa transgene and lineage depletion only after transduction in this protocol minimizes biases due to lineage-specific cell cycle inhibition. Consistent with the conclusion that C/EBPa can direct monopoiesis as well as granulopoiesis, transduction of B-or T-cell progenitors with C/EBPa induces macrophage but not neutrophil development (Heavey et al., 2003; Xie and Graf, 2004; Laiosa et al., 2006) ; transplantation of mice with marrow transduced with C/EBPa increases the proportion of monocytes from 13 to 88%, while inhibiting erythropoiesis (Suh et al., 2006) ; and CLP or MEP isolated from mice expressing a C/EBPa-ER(T) transgene from the H2K promoter develop into macrophages upon exposure to 4-hydroxytamoxifen (Fukuchi et al., 2006) . In contrast, C/EBPa-ER converts CD71
þ erythroid cells to granulocytes (Cammenga et al., 2003) . Perhaps GATAbinding protein 1 (GATA-1), which can directly bind and inhibit PU.1 (Rekhtman et al., 1999; Zhang et al., 1999) , prevents monopoiesis in this setting.
PU.1
PU.1 binds as a monomer to the consensus DNA site 5 0 -AAAG(A/C/G)GGAAG-3 0 via its C-terminal Ets domain and activates transcription via its N-terminal glutamine-rich and acidic domains (Klemsz et al., 1990) . PU.1 is expressed in B-lymphoid, early T-lymphoid, granulocytic and monocytic cells (Klemsz et al., 1990; Chen et al., 1995a; Spain et al., 1999) . LMP express higher levels of PU.1 than MEP (Arinobu et al., 2006) . PU.1(À/À) mice lack B cells and monocytes and have greatly reduced neutrophils McKercher et al., 1996) . At the progenitor level, these mice have markedly diminished CLP and GMP numbers with increased MEP . Expression of the MCSFR or granulocyte colony stimulating factor receptor (GCSFR) in PU.1(À/À) marrow cells did not rescue myeloid development, indicating that PU.1 is required beyond induction of these cytokine receptors (DeKoter et al., 1998; Henkel et al., 1999) . Expression of low levels of PU.1 in PU.1(À/À) cells induces granulopoiesis, whereas high levels induce monopoiesis (Dahl et al., 2003; Laslo et al., 2006) . Genetic analysis also indicates that a higher level of PU.1 favors monocytic over granulocytic development: lack of one PU.1 allele favors neutrophil development from embryonic stem cells in vitro and encourages neutrophil development in vivo in the absence of G-CSF (Dahl et al., 2003) ; deletion of the PU.1 distal enhancer located at À14 kb results in 20% of normal PU.1 expression and loss of monopoiesis with preservation of granulopoiesis (Rosenbauer et al., 2004) ; and CRE-mediated deletion of PU.1 in adult mice preserves granulocytes at the expense of monocytes (Dakic et al., 2005) . However, the latter two studies found loss of MCSFR with preservation of GCSFR expression, leaving open the question of whether increased PU.1 favors monopoiesis independent of its effect on receptor expression.
Investigating why the MCSFR gene is more sensitive to PU.1 levels than the GCSFR gene might provide mechanistic insight as to why increased PU.1 is required for monopoiesis. In this regard, PU.1 is sufficient to reorganize the chromatin structure of the MCSFR promoter in myeloid progenitors, but requires onset of Egr-2 expression to fully activate the intronic regulatory region designated the FIRE enhancer (Krysinska et al., 2007) . PU.1 binds and activates its own promoter and distal enhancer, potentially to variable degrees in different lineages and developmental stages dependent on cooperating factors (Chen et al., 1995b; Okuno et al., 2005) . Onset of PU.1 expression in HSC or LMP may depend on Runx1-mediated activation via the PU.1 distal enhancer (Huang et al., 2007a) , with C/EBPa then directing LMP or CMP to the GMP stage and beyond, in part, via further PU.1 induction. The C/EBPb and PU.1 DNA-binding domains directly interact (Yang et al., 2000) , and promoter-bound C/EBPb increases PU.1 interaction with a nearby cis element in the IL-1b promoter, augmenting gene induction (Grondin et al., 2007) . C/EBPa has the potential to similarly cooperate with PU.1 as these proteins also directly interact (Reddy et al., 2002) . Increased PU.1 in myeloid cells may also facilitate its ability to directly bind and repress transactivation by GATA-1 to downmodulate the erythroid program, just as GATA-1 inhibits PU.1 activity in cooperation with Rb to ensure continued maturation of erythroid and megakaryocytic cells (Rekhtman et al., 1999 (Rekhtman et al., , 2003 Zhang et al., 1999 Zhang et al., , 2000 Stopka et al., 2005) .
In addition to favoring monopoiesis over granulopoiesis, increased PU.1 expression also favors myeloid over lymphoid development: expression of exogenous PU.1 in PU.1(À/À) progenitors induces B cells at lower levels and monocytes at higher levels (DeKoter and Singh, 2000); exogenous PU.1 converts B or T cells to monocyte/macrophages but not granulocytes (Xie and Graf, 2004; Dionne et al., 2005; Laiosa et al., 2006) ; and PU.1 knockdown in embryonic stem cell-derived CD34 þ cells favors B-cell formation (Zou et al., 2006) . The ability of both C/EBPs and PU.1 to reprogram lymphoid cells to the monocyte lineage likely reflects the ability of C/EBPs to bind to and activate the PU.1 promoter and distal enhancer. 32Dcl3 cells, a model of granulocyte progenitors, differentiates to neutrophils in response to exogenous C/EBPa-ER but not PU.1-ER, indicating that C/EBPa does more than induce PU.1 to facilitate terminal granulopoiesis or monopoiesis (Wang et al., 1999) . Lack of granulocytic development from lymphoid cells transduced with C/EBPa or PU.1 likely reflects their inability to induce a critical cooperating factor in that context. The combination of C/EBPa-ER and exogenous GCSFR signals, but not either alone, allows Ba/F3 pro-B cells to express early myeloid markers, suggesting that unique, myeloid cytokine signals potentiate the response to C/EBPa (Wang et al., 2001) . Finally, the transition from monocyte to Langerhans dendritic cells requires downmodulation of C/EBPa with retention of PU.1 expression Ginhoux et al., 2006) .
Interferon regulatory factor 8 and interaction with PU.1
Phosphorylation of PU.1 within its central PEST domain on serine 148 allows interaction with interferon regulatory factor 4 (IRF-4) or IRF-8, the latter also designated ICSBP (Eisenbeis et al., 1995; Meraro et al., 1999) . IRF-4 and IRF-8 each contain amphipathic a-helices whose polar surfaces are critical for interaction with PU.1 (Ortiz et al., 1999) . Tyrosine phosphorylation of IRF-8 prevents it from directly binding DNA, but allows it to do so after interaction with other IRFs or PU.1 (Sharf et al., 1997) . IRF-8 associates with IRF-1 or IRF-2 to bind an interferon-stimulated response element with two GAAANN half sites, and IRF-8:PU.1 complexes bind an Ets/IRF composite element containing a GGAA PU.1 site either preceded or followed by a single GAAANN element (Meraro et al., 2002; Tamura et al., 2005) . The SHP2 protein tyrosine phosphatase acts on IRF-8 to prevent it from inducing the NF1 gene (Huang et al., 2007b) . SHP2 activity diminishes during myeloid differentiation, allowing increased IRF-8 activity and facilitating differentiation in cooperation with PU.1 (Kautz et al., 2001; Kakar et al., 2005) .
IRF-8(À/À) mice have reduced macrophages and increased granulocytes and form increased CFU-G at the expense of CFU-M in G-CSF, M-CSF or GM-CSF (Holtschke et al., 1996; Tsujimura et al., 2002) . Introduction of IRF-8 into IRF-8(À/À) marrow cells rescues monopoiesis at the expense of granulopoiesis dependent on its PU.1 interaction and DNA-binding domains (Tsujimura et al., 2002) . Integrating these observations with the finding that increased PU.1 levels are required for monopoiesis as compared to granulopoiesis leads to the suggestion that higher levels of PU.1 facilitate interaction with IRF-8 to regulate genes required for monocyte lineage commitment and maturation via Ets/IRF composite elements.
AP-1 and interaction with Maf, PU.1 or C/EBP AP-1s, like the C/EBPs, are a subfamily of bZIP transcription factors. Within the AP-1 family, Jun proteins heterodimerize with c-Fos, FosB, Fra1 or Fra2 to bind DNA at sites having the 5 0 -TGA(C/G)TCA-3 0 consensus. c-Jun, JunB and JunD levels increase during monocytic maturation, and exogenous c-Fos or c-Jun induce monocytic differentiation of myeloid cells (Lord et al., 1993; Szabo et al., 1994; Li et al., 1994) . Phorbol esters, which activate protein kinase C (PKC)s, induce monocytic maturation of a variety of myeloid cell lines, and activated PKCa directs monocytic maturation of transduced CFU-GM (Pierce et al., 1998) . PKCa activates c-Jun kinase (JNK)2 via direct phosphorylation of S129, and PKCd phosphorylates S129 of JNK1 (Lopez-Bergami et al., 2005; Liu et al., 2006) . PKCd also activates JNK via activation of MEKK1, which then kinases MKK7, a JNK kinase (Yoshida et al., 2002) . JNK1 and JNK2 are ubiquitous, and their double knockout is embryonic lethal. JNK3 is not present in hematopoietic cells. The JNK inhibitor SP600125 reduces the number of macrophages developing from murine marrow cells cultured in the presence of M-CSF (Himes et al., 2006) . Activated JNK phosphorylates c-Jun and c-AMP-dependent transcription factor (ATF2), leading to their stabilization. c-Jun:ATF2 trans-activates the c-Fos promoter, and c-Fos:c-Jun subsequently induces c-Jun transcription (Shaulian and Karin, 2001; Weston and Davis, 2002) . Perhaps this signaling pathway is preferentially activated by M-CSF as compared the G-CSF signals during normal hematopoiesis. The finding that the MCSFR binds phospholipase C-g via Y721 whereas such interaction has not been described for the GCSFR supports this proposal (Bourette et al., 1997) . Activated phospholipase C-g releases diacylglycerol, which activates PKC.
Both c-Jun(À/À) and JunB(À/À) cells develop all the hematopoietic lineages in vivo, but as with the C/EBPs redundancy might obscure a phenotype in these mice (Eferl et al., 1999) . Mice lacking JunB specifically in hematopoietic cells develop increased granulocytes (Passegue et al., 2001) ; this may represent loss of the anti-proliferative effect of JunB rather than an effect on lineage commitment.
In addition to Fos:Jun interactions, the MafB bZIP transcription factor can zipper with c-Fos, and c-Maf can heterodimerize with c-Jun, JunB or c-Fos, to bind extended AP-1 sites with consensus 5 0 -TGA(C/G)TCAG CA-3 0 (Kataoka et al., 1994) . MafB is expressed exclusively in monocyte/macrophage cells within hematopoiesis (Sieweke et al., 1996) . Exogeneous MafB or c-Maf leads to monocytic development of myeloid cell lines (Hegde et al., 1999; Kelly et al., 2000) . Downregulation of MafB is required for myeloid dendritic cell maturation (Bakri et al., 2005) . MafB(À/À) fetal liver cells have normal numbers of myeloid CFUs, but these immature cells are unable to give rise to F4/80-expressing macrophages, suggesting a role for MafB and perhaps MafB:Fos complexes late but not early in monocyte lineage development (Aziz et al., 2006; Moriguchi et al., 2006) . c-Jun directly interacts with and enhances the ability of PU.1 to activate the MCSFR and IL-1b promoters in the absence of an AP-1 cis element, and PU.1 and c-Jun cooperatively regulates the monocytic macrosialin and scavenger receptor promoters via distinct binding sites (Moulton et al., 1994; Bassuk and Leiden, 1995; Li et al., 1998; Behre et al., 1999; Grondin et al., 2007) . Interaction of c-Jun homodimers with PU.1 depends on integrity of residues in the c-Jun BR and is augmented by contact of PU.1 with C/EBPb bound to DNA nearby (Grondin et al., 2007) . The C-terminal zinc finger of GATA-1 competes with the DNA-binding BR of c-Jun for interaction with the Ets domain of PU.1 Liew et al., 2006) . This is a potential mechanism to prevent myeloid gene activation in erythroid cells. The C/EBPa LZ also competes with c-Jun for interaction with PU.1 in the absence of DNA (Reddy et al., 2002) , but when bound to DNA C/EBPa may in specific contexts, like C/EBPb, augment PU.1 activity as these factors cooperatively activate myeloid promoters (Oelgeschla¨ger et al., 1996) . c-Jun rescues monocytic differentiation in PU.1-knockdown marrow cells (Steidl et al., 2006) , but its effect in PU.1(À/À) cells has not been evaluated. Also of note, c-Jun and JunB levels are reduced in PU.1-knockdown HSCs, although PU.1 binds the JunB but not the c-Jun promoter (Steidl et al., 2006) . c-Jun or c-Fos interacts with and prevents C/EBP bZIP DNA-binding, even if the c-Fos or c-Jun BRs are deleted, suggesting direct interaction via their LZ domains (Hsu et al., 1994) . Similarly, C/EBPa binds c-Jun, but not if the LZ is deleted from either of these proteins, and c-Jun inhibits C/EBPa DNA-binding (Rangatia et al., 2002 (Rangatia et al., , 2003 . These studies suggest, but do not prove, direct zippering (hydrophobic surface interaction) between c-Jun or c-Fos and C/EBPa or C/EBPb. Challenging this conclusion are the results obtained with a zipper peptide chip in which none of the AP-1 or Maf LZs interact with C/EBP LZs, though Jun:Jun, Jun:Fos and MafB:Fos interactions are detected (Newman and Keating, 2003) . A recent set of experiments confirms C/EBP:AP-1 zippering. In a zipper swap:gel shift assay, heterologous LZs were substituted in place of the C/EBPa LZ in the full-length protein. These were incubated with the C/EBPa bZIP domain and a radiolabeled C/EBP-binding site. Coiledcoil LZ interaction positions the two C/EBPa BRs properly for DNA binding. C/EBPa or C/EBPb LZs zippered with the c-Jun, JunB and c-Fos but not the c-Maf or MafB LZs. Also, co-immunoprecipitation assay demonstrated that C/EBPa interacts with endogenous or exogenous c-Jun, JunB or c-Fos but not if two leucines in the LZ are changed to valine. Interaction with the AP-1 proteins by co-immunoprecipitation was weaker than with C/EBPb, perhaps explaining their lack of detection on the zipper chip (Cai et al., 2006) . A scheme for predicting interaction strengths between LZs enumerates contacts between acidic residues D or E and basic residues R or K in the e and g salt bridge positions (Vinson et al., 1993) . C/EBPa:C/EBPa, c-Fos:c-Jun or c-Fos:JunB has four, C/EBPa:c-Jun has two and C/EBPa:JunB or C/EBPa:c-Fos has three LZ salt bridges. The relative weakness of C/EBP:AP-1 interactions suggests that gene activation via novel DNA elements rather than cross-inhibition of binding to C/EBP and AP-1 sites will predominate in vivo. To evaluate activities of specific homodimers or heterodimers, we utilized GCN4 LZs with eight acid (LZE) or eight basic (LZK) residues in their salt bridge positions (O'Shea et al., 1993) . C/EBPaLZE:C/EBPaLZK preferentially binds a C/EBP site, c-JunLZE:c-FosLZK an AP-1 site and C/EBPaLZE:c-JunLZK a hybrid element. In murine myeloid progenitors, C/EBPa:c-Jun or C/EBPa:c-Fos LZE:LZK heterodimers induced monocyte as opposed to granulocyte lineage commitment with markedly increased potency compared with C/EBPa homodimers or c-Jun:c-Fos heterodimers, demonstrating a positive functional consequence of C/EBP:AP-1 bZIP subfamily interaction (Cai et al., 2006) .
NF-jB and interaction with C/EBP
NF-kB is a key regulator of the inflammatory response in mature granulocytes and monocytes. There are five NF-kB family members, c-Rel, Rel A or p65, Rel B, NFkB1 or p50 and NF-kB2 or p52. Each has a 300 aminoacid Rel homology domain that mediates dimerization, DNA binding and trans-activation. p65 has a transactivation domain, and p50 can repress transcription. The p50:p65 heterodimer predominates in most cell types. p52 partially substitutes for the lack of p50 and cRel for the lack of p65 (Hoffmann et al., 2003) . C/EBPb and NF-kB cooperatively bind and activate the IL-6, IL-8, G-CSF, serum amyloid, intercellular adhesion molecule 1, superoxide dismutase and Mediterranean fever promoters during the inflammatory response in myeloid and other cells (Dunn et al., 1994; Kunsch et al., 1994; Xia et al., 1997; Maehara et al., 1999; Papin et al., 2003) . Co-immunoprecipitation demonstrates interaction of bacterially expressed C/EBPa or C/EBPb with bacterially expressed or in vitro translated p50 or p65, mapping to the bZIP domain of C/EBP and to the Rel homology domain of p65 (Matsusaka et al., 1993; Stein et al., 1993) . C/EBPa or C/EBPb cooperate with NF-kB p50 to induce bcl-2 transcription and inhibit apoptosis in hematopoietic cells; the C/EBPa BR3 or R300G variants, having four or one altered residues in the BR, demonstrate reduced binding to p50 but not p65 and an inability to induce bcl-2 (Paz- Priel et al., 2005) . This study also found that endogenous C/EBPa preferentially interacts with endogenous p50 compared with p65 in extracts from the HL-60 or U937 myeloid cell lines.
In contrast to wild-type C/EBPa, favoring monocytic lineage commitment, the C/EBPa BR3 variant favors granulopoiesis when expressed in myeloid progenitors . The BR3 mutant also specifically lacks the ability to inhibit phorbol ester-mediated induction of JunB in the 32DPKCd cell line (Liu et al., 2003) . These findings lead to the speculation that C/EBPa and NF-kB p50 directly interact to cooperatively induce a subset of genes in immature myeloid cells required for monocyte development. Although myeloid defects have not been observed in p50(À/À) mice, other NF-kB family members may compensate (Sha et al., 1995) . In more mature myeloid cells, phosphorylationdependent interaction of the N-terminal region of C/EBPe with NF-kB p65 contributes to transcriptional induction (Chumakov et al., 2007) .
Retinoic acid and vitamin D receptors
0 via their zinc-finger domains as heterodimers with RXR proteins (Naar et al., 1991; Umesono et al., 1991) . RARs are widely expressed, with RARa preferentially found in myeloid cells (de The et al., 1989) . Dominant inhibition of RARa arrests granulopoiesis at the promyelocyte stage (Tsai and Collins, 1993) . RARa1(À/À)RARg(À/À) neutrophils do not proceed past the myelocyte stage (Labrecque et al., 1998) . Regulation of the C/EBPe promoter by RARa may account in part for the role of RARs in granulopoiesis . RARs also activate the CD18 promoter in maturing myeloid cells, in cooperation with the Ets family member GA-binding protein, and mediate their cell cycle arrest (Bush et al., 2003; Walkley et al., 2004) . Retinoic acid increases the formation of CFU-G at the expense of CFU-M from marrow progenitors, and 1a,25-dihydroxyvitamin D 3 , which activates the related vitamin D receptor (VDR):RXR complex, increases CFU-M at the expense of CFU-G (Douer and Koeffler, 1982; Koeffler et al., 1984) . When retinoic acid and vitamin D are added together, monocytic development is induced, and VDR:RXR complexes bind and repress RAR:RXR-responsive elements, suggesting that ligandbound VDR drives monopoiesis by interacting with elements unaffected by RAR while inhibiting granulopoiesis via dominant inhibition of RAR-regulated genes (Bastie et al., 2004) . Downmodulation of RXRa, the common partner of RAR and VDR, is induced by G-CSF but not M-CSF and is required for terminal granulocytic but not monocytic maturation (Taschner et al., 2007) . How RAR and VDR activation and later downregulation integrates with additional transcriptional controls to mediate myeloid lineage specification remains to be further elucidated.
Gfi-1, Egr-1, 2, CAAT displacement protein and HoxA10 repress terminal differentiation Gfi-1 binds DNA via a C-terminal zinc-finger domain and represses transcription via its N-terminal Snail/GFi-1 (SNAG) domain Zweidler-Mckay et al., 1996) . Gfi-1 is expressed in lymphoid and granulocytic cells but not in the monocyte lineage (Karsunky et al., 2002; Hock et al., 2003; Duan and Horwitz, 2003) . Gfi-1(À/À) mice or a patient expressing a mutant Gfi-1 display defects in neutrophil maturation subsequent to the promyelocyte stage; abnormal cells are present that retain primary granules and ring-shaped nuclei, but lack secondary and tertiary granule proteins and aberrantly express monocyte-restricted genes (Hock et al., 2003; Person et al., 2003) . These observations contribute to a model in which Gfi-1 represses a gene encoding an inducer of monopoiesis, such as PU.1, with PU.1 normally activating a repressor of terminal granulopoiesis (Laslo et al., 2006) . Analysis of genes induced by high levels of PU.1 identified Egr proteins and Nab-2 as candidates for repressing granulopoiesis, while at the same time contributing to monopoiesis (Laslo et al., 2006) . Egr-1 and Egr-2 are zinc-finger transcription factors that bind the consensus 5 0 -GCGGGGCG-3 0 and can activate or repress transcription (Crosby et al., 1991) . Egr-1 stimulates monocyte differentiation in myeloid cell lines and murine marrow progenitors at the expense of granulopoiesis (Nguyen et al., 1993; Krishnaraju et al., 1995 Krishnaraju et al., , 1998 Krishnaraju et al., , 2001 . Egr-1(À/À) mice develop normal numbers of macrophages, as do Egr-2(À/À) fetal liver cells; however, expression of a dominant-negative Egr protein or analysis of Egr-1(À/À);Egr-2( þ /À) marrow cells uncovers defective monocytic maturation in M-CSF but not in GM-CSF (Lee et al., 1996; Laslo et al., 2006) . Gene activation by Egr-1 or Egr-2 apparently stimulates monocytic maturation. Consistent with the idea that Egr:Nab-2 complexes repress granulopoiesis, Egr-2 or Nab-2 knockdown induce neutrophilic genes including Gfi-1 in a myeloid cell line, and Egr-2/Nab-2 represses the Gfi-1 promoter via an Egrbinding site (Laslo et al., 2006) . The same study found that Gfi-1 represses the Egr-2 promoter, providing cross-inhibition that stabilizes the neutrophil fate. Gfi-1 also directly interacts with and represses trans-activation by PU.1, providing an additional mechanism favoring granulopoiesis (Dahl et al., 2007) .
CAAT displacement protein (CDP) is a widely expressed protein that represses transcription by competition with transactivators for sites which loosely resemble a 5 0 -CCAAT-3 0 motif (Barberis et al., 1987; Luo and Skalnik 1996) . Diminution of CDP DNA-binding during granulocyte maturation and its ability to repress the gp91-phox promoter suggests that downmodulation of CDP is required for terminal neutrophil differentiation (Skalnik et al., 1991) . 32Dcl3 cells expressing exogenous CDP do not express C/EBPe or secondary granule proteins in G-CSF (Lawson et al., 1998; Khanna-Gupta et al., 2001) . Consistent with the need to downmodulate CDP for terminal granulopoiesis, mice transgenically expressing CDP from the MMTV LTR develop a myeloproliferative disease with increased neutrophils infiltrating marrow and spleen (Cadieux et al., 2006) .
HoxA10 is preferentially expressed in immature myeloid cells within hematopoiesis and exogenous HoxA10 stimulates monopoiesis while blocking terminal granulopoiesis (Sauvageau et al., 1994; Lawrence et al., 1995; Taghon et al., 2002) . HoxA10 represses the gp91-phox and p67-phox promoters in immature myeloid cells dependent on the presence of the SHP2 tyrosine phosphatase, which acts directly on HoxA10 to allow DNA-binding (Eklund et al., 2000; Lindsey et al., 2007) . In contrast, tyrosine phosphorylation of HoxA9 potentiates its ability to bind and activate these genes in maturing cells that have reduced SHP2 (Bei et al., 2005) .
Summary and perspectives for the future Figure 1 provides a model of myeloid lineage development. PU.1 appears to specify the lymphoid-myeloid and GATA-1 the erythroid-megakaryocyte hematopoietic branches, with PU.1:GATA-1, and possibly PU.1:GA-TA-2, cross-inhibition maintaining commitment in either direction. C/EBPa then specifies the GMP stage. Crossinhibition between C/EBPa and Pax5 or Notch may serve to fix this commitment decision. Increased PU.1 activity favors monocyte over granulocyte lineage commitment. This increase may result from C/EBPa activation of the PU.1 gene or as a result of PU.1 interaction with c-Jun. C/EBPa:c-Jun, C/EBPa:c-Fos or C/EBPa:NF-kB heterodimers may induce PU.1 or a protein that cooperates with PU.1 to favor monocytic commitment. Perhaps MCSFR signals favor increased PU.1 activity via one of these mechanisms compared to GCSFR signals. RARs contribute to granulocytic commitment and the VDR to monocytic commitment. PU.1 induction of Egr-1 or Egr-2 facilitates maturation along the monocyte lineage, while C/EBPa induction of C/EBPe and perhaps Gfi-1 enables granulocytic maturation. Downmodulation of SHP2 activates IRF-8 while inactivating HoxA10 to contribute to monocytic and granulocytic maturation. MafB facilitates late monocyte and loss of CDP late granulocyte development. Cross-inhibition between Gfi-1 and Egr/ Nab-2 maintains myeloid lineage fidelity.
Many questions remain. Are increased PU.1 levels required only at a critical developmental stage to specify monocytic commitment? What cytokine signals and transcription factors cooperate to elevate PU.1 at the prescribed time? What are the critical genetic or protein targets of elevated PU.1 that allow monocyte lineage progression, and why are they insensitive to lower levels of PU.1? Does VDR, AP-1 or C/EBPa:AP-1 complex, IRF-8, or Egr-1/Egr-2 contribute to monocyte lineage specification or RAR to granulocyte specification and not only lineage maturation, and do they do so in cooperation with, independent of or via induction of PU.1? What are the roles of transcriptional co-activators and corepressors and chromatin structure in myeloid development? How does crosstalk with cell cycle pathways influence terminal maturation? Does NF-kB, which is activated in leukemic stem cells (Guzman et al., 2001) , play a role in normal myeloid stem cells in cooperation with C/EBPa? Is commitment to granulopoiesis a default pathway that occurs when PU.1 is not induced sufficiently, or are there positive inducers of this lineage that increase due to GCSFR signals. Candidates for the latter include STAT3 (de Koning et al., 1996; Shimozaki et al., 1997) and Id1-regulated basic helix-loop-helix proteins (Leeanansaksiri et al., 2005; Jankovic et al., 2007) . The answers to these questions will provide important lessons in developmental biology, insights into myeloid transformation that will guide therapies aimed at inducing differentiation, and tools for expanding normal myeloid cells from hematopoietic or even embryonic stem cells. Figure 1 A model for the transcriptional regulation of granulocyte and monocyte lineage commitment and maturation. Under the influence of GATA-binding protein 1 (GATA-1), the hematopoietic stem cell (HSC) differentiates into the megakaryocyte-erythroid progenitor (MEP). PU.1 directs the HSC to develop into a lymphoid-myeloid progenitor (LMP), which then further commits to the common lymphoid progenitor (CLP) branch or, directed by CCAAT/enhancer-binding protein alpha (C/EBPa), to the granulocytemonocyte progenitor (GMP) branch. Cross-inhibition between GATA-1 and PU.1 serves to maintain HSC developmental fates, and similar cross-inhibition between C/EBPa and lymphoid regulators such as Pax5 and Notch may maintain CLP developmental decisions. Increased PU.1 activity directs the GMP to further commit to the monocytic lineage. C/EBPa induction of PU.1 transcription helps elevate PU.1 activity as does PU.1 interaction with c-Jun. AP-1 and NF-kB proteins may also have a role at this stage of hematopoiesis via direct interaction with C/EBPa, either contributing to PU.1 induction or activating a parallel pathway. C/EBPa and PU.1, at reduced levels, are also required for granulopoiesis, but another factor, perhaps a protein regulated by Id1, may be essential for commitment to the granulocyte lineage. VDR, IRF-8, MafB, Egr-1 and Egr-2 direct monocytic maturation, and RARs and C/EBPe act similarly during terminal granulocytic development. Loss of CDP-and HoxA10-repressive activities and onset of Gfi-1-mediated repression contributes granulopoiesis. Cross-inhibition between Gfi-1 and Egr-1,2/Nab2 co-repressor complexes maintains GMP developmental decisions.
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